- 1 Are depot anti-psychotics associated with longer
- ² persistence in treatment compared with oral
- antipsychotics among patients with Schizophrenia?
- 4 5

6 ABSTRACT

Aim: Non-adherence with antipsychotics is associated with poor outcomes in patients with schizophrenia. It was anticipated that drop-out from treatment due to non-compliance with oral antipsychotics could be abated with the use of depot antipsychotics. However previous studies are divergent regarding the association between persistence in treatment and the use of depot antipsychotics. This study aimed to compare treatment persistence among out-patients with schizophrenia receiving depot versus oral antipsychotics in Lagos, Nigeria.

Methodology: Relevant clinical data of out-patients with schizophrenia (n=160) were retrieved one year post-hospitalisation at a public psychiatric facility in Nigeria. Treatment persistence (time to all cause treatment discontinuation) among the cohort of patients was determined using the Kaplan-Meier Survival analyses. Persistence in treatment between patients receiving depot versus oral antipsychotic medications alone was compared using the log rank test.

18 **Results**: Nearly half (49.1%) of the cohort dropped out of treatment within one month of discharge,

- 19 while 18.2% persisted for one year. There was no significant difference (p=0.727) in the mean
- 20 duration of treatment persistence between patients receiving depot antipsychotics (17.4(±2.4) weeks),
- 21 and those receiving oral medications alone (19.4 (±2.2) weeks).

- 23 Conclusion: There is a high rate of drop-out from treatment among patients with schizophrenia, after
- 24 discharge from in-patient care. Prescription of depot medications was not associated with longer
- 25 persistence treatment in the studied cohort. This finding highlights the need to develop interventions
- 26 to facilitate treatment persistence among patients with schizophrenia.
- 27

28 1. INTRODUCTION

29 Schizophrenia is a severe disorder that interferes with functioning in multiple neuro-psychological domains including cognition, perception, and thought systems. Schizophrenia usually runs a chronic 30 31 course which may be punctuated by intermittent periods of remission and relapse. Anti-psychotics are 32 the mainstay in the treatment of schizophrenia, and are effective in the treatment of psychotic 33 symptoms, as well as reducing the risk of relapse and re-hospitalisation [1, 2]. Despite the availability and effectiveness of anti-psychotics in the therapy of schizophrenia, research 34 35 has consistently shown a low rate of treatment adherence or persistence in treatment. More than half of patients with schizophrenia discontinue anti-psychotics treatment within the first year of onset of 36 37 treatment [3-5]. Non-persistence in treatment has dire clinical, social and public health implications 38 including increased risk of relapse, re-hospitalisation, increased burden on emergency services, 39 suicide and mortality [6-10]. 40 In terms of efficacy in the treatment of the positive and negative symptoms of schizophrenia, evidence has shown that depot antipsychotics are at least at par with their oral equivalent, if not better [11-17]. 41 42 In addition, depot formulations are expected to address non-compliance attributable to forgetting to 43 use medications or lack of insight; which are quite common among patients with schizophrenia [15-44 17]. On the flip side, pain at injection sites, perception of coercion or lack of autonomy and stigma 45 may not favour adherence with depot anti-psychotics [15-17]. With the advent of long acting injections, it was envisaged that these medications would facilitate 46 47 monitoring of treatment compliance, thereby guaranteeing administration of medications and 48 transparency of adherence [15-17]. Consequently, it was anticipated that this would allow the

clinicians to be promptly alerted and intervention instituted if patients fail to receive their depot medications. The anticipation that depot antipsychotics would guarantee treatment adherence and persistence in treatment has not been consistently substantiated by extant research evidence. While several authors reported a longer persistence in treatment or better adherence with depot versus oral antipsychotics in naturalistic samples, results of randomised control trials and meta-analyses contradict these findings [15-22].

A few studies have reported high rates of non-compliance with medications or clinic appointments 55 56 among patients with chronic psychiatric disorders in sub-saharan Africa [23-28]. However, there is 57 dearth of evidence on treatment adherence or treatment persistence with depot versus oral antipsychotics in Africa. A retrospective study conducted at a tertiary mental health service in Nigeria 58 59 found that less than a quarter of patients with schizophrenia persisted in treatment for one year [27]. A more recent study conducted at a psychiatric hospital in south-west Nigeria reported similar findings 60 [28]. However, these studies did not investigate the relationship between route of administration of 61 62 medications and treatment persistence. The current study aimed to compare persistence in treatment 63 between patients with schizophrenia receiving depot antipsychotics and those receiving oral antipsychotics after discharge from in-patient care to out-patient clinic in a Nigerian psychiatric 64 65 hospital.

66

67 METHODOLOGY

The methodology of the current study has been previously described by the author in a recent study comparing treatment persistence among patients with schizophrenia receiving first-generation versus second generation oral antipsychotics [28]. The study was conducted at a public tertiary mental health care facility, Federal Neuro-Psychiatric Hospital Yaba Lagos, located in south-West Nigeria. The hospital has an in-patient facility with 500 beds and out-patient clinics attended by more than a thousand patients weekly. The out-patient clinics are open on weekdays from 8am to 4pm, except on Wednesdays. The study design was a retrospective cohort study.
Patients with schizophrenia hospitalised over a six-month period between January and June 2012

Patients with schizophrenia hospitalised over a six-month period between January and June 2012 and subsequently discharged to attend follow-up appointment at the out-patient clinic constituted the study population. As part of a larger study of clinical outcomes in patients with schizophrenia, the medical records were reviewed between October and December 2013 to assess persistence in treatment over a period of one year after discharge from in-patient care to out-patient clinic. Inclusion criteria for recruitment into the sample included case-notes with documented diagnoses of schizophrenia by consultant psychiatrists according to the ICD-10 diagnostic criteria [29]. Patients less than 18 years and greater than 65 years were excluded from the sample. Bata retrieved for each patient included socio-demographic characteristics, clinical diagnosis, number of episodes of illness, number of psychiatric hospitalisations, prescribed class and route of administration of anti-psychotic medications (e.g. typical or atypical and depot versus oral), and attendance of out-patient clinic appointment/prescription refill over a period of one year after discharge from the hospital (treatment persistence).

Treatment persistence was defined as the time to all-cause treatment discontinuation and calculated as the total number of consecutive weeks from the date of hospital discharge to the onset of the first treatment gap of > 14 consecutive days. Similar definition has been used by previous researchers on this subject [4, 30]. Treatment gap commenced from the date of the missed clinic appointment/ prescription refill. Research indicates that medical records of clinic attendance/prescription refill highly correlate with pharmacy refill and these indices are valid indirect measures of treatment adherence [4, 31-32].

95 Routinely, the standard protocol at the facility where the study was conducted is such that patients with schizophrenia receive take-home prescriptions for anti-psychotic medications, which are 96 97 collected from the hospital pharmacy before discharge. The quantities of drugs prescribed are sufficient until the date of the scheduled follow-up appointment at the out-patient clinic. At each 98 99 follow-up visit, prescriptions are refilled after consultation and documented in the clinical records. All 100 the patients on depot medications were on typical (first-generation) depot antipsychotics such as 101 fluphenazine, depixol and clopixol in addition to oral antipsychotics. The oral antipsychotics regularly 102 available in the hospital at the time of the study included olanzapine, risperidone, clozapine, 103 chlorpromazine, trifluoperazine and haloperidol. Institutional approval was obtained from the 104 Research and Ethical Committee.

105 **Statistical Analysis**: Data was analysed with IBM- SPSS (version 20). Kaplan-Meier Survival 106 analyses was used to determine the major outcome of interest; persistence in treatment. Participants 107 who had not dropped out of treatment before the end of the one year period of review were right 108 censored. The log-rank test was used to compare treatment persistence between patients receiving 109 depot versus oral antipsychotics.

111 **2. RESULTS**

112	The current sample	consisted of 160	patients with	schizophrenia	discharged from	in-patient to out-
-----	--------------------	------------------	---------------	---------------	-----------------	--------------------


- 113 patient clinic at a public psychiatric Hospital in Nigeria. There were more females (59.4%) than males,
- and less than one third (31.3%) were married. The mean age of the patients was 38.7 (±11.4) years
- 115 (Table 1). The majority attained secondary (35%) or tertiary (43%) levels of education, but only 36.5%
- 116 were employed. Among the cohort that constituted the study sample, the median number of episodes
- 117 of schizophrenia was 2, while the median number of psychiatric hospitalisation was 1. Depot
- antipsychotics were prescribed for 48.1% of the patients, while 51.9% received oral antipsychoticsalone.

121		N= 160	
122	Variable	n	(%)
123			
124	Gender		
125	Male	65	(40.6)
126	Female	95	(59.4)
127	Marital status		
128	Married	50	(31.3)
129	Single	110	(68.7)
130	Employment status		
131	Employed	58	(36.5)
132	Unemployed	102	(63.5)
133	Level of education		
134	No formal education	5	(3.1)
135	Primary	18	(11.3)
136	Secondary	56	(35.0)
137	Tertiary	69	(43.1)
138	*		
139			

120 Table 1: Socio-demographic characteristics of the patients in the sample

- Based on the earlier defined criteria, only 50.9% of patients with schizophrenia persisted in treatment 141 142 one month after discharge from the hospital. Subsequently, there was a gradual decline in persistence in treatment. By the end of the third and sixth month, 45.9% and 28.9% of the patients 143 144 persisted in treatment respectively. Only 18.2% had not defaulted from treatment one year after 145 discharge from the hospital. 146 The mean time to all cause treatment discontinuation calculated by the Kaplan-Meier survival analysis (figure 1) indicated that the mean duration of treatment persistence among the patients was 18.5 147 148 (±1.6) weeks (95% C.I= 15.4-21.6). Among patients receiving depot antipsychotics, the mean duration 149 of treatment persistence was 17.4(±2.4) weeks (95% C.I= 12.8-22.1), while those receiving oral medications alone had mean duration of treatment persistence of 19.4 (±2.2) weeks (95% C.I= 15.2-150 151 23.7). Using the log-rank (Mantel-cox) test, a comparison of the survival times between both groups of 152 patients revealed no statistically significant difference in treatment persistence (chi-square=0.122, p=0.727). 153 Figure1: Kapan-Meier survival analysis curve comparing treatment persistence between 154
- 155 patients using depot versus oral antipsychotics

Survival Functions



157

158 3. DISCUSSION

This study compared persistence in treatment between out-patients with schizophrenia receiving depot antipsychotic medications versus those receiving oral antipsychotics alone, following discharge from a tertiary psychiatric care facility in south-west Nigeria. The socio-economic profile of the patients in this cohort is consistent with the pattern of impairment in social and occupational domains typically seen in patients with schizophrenia [33].

- 164 Within one month of discharge from in-patient care, nearly half of the sample had dropped out of
- 165 treatment, and by the end of the third month post-discharge, only 46% persisted in treatment. A study
- 166 of post-discharge treatment adherence among patients discharged from a Psychiatric Hospital in
- 167 Nigeria similarly reported that only 50.6% of the patients were persistent in treatment until the 3rd
- 168 month post-hospitalisation [24]. The current study also found that about 4 out of 5 patients with

169 schizophrenia had dropped out of treatment within one year of discharge to out-patient care. This

170 finding is consistent with that reported among patients with first episode schizophrenia in south-west

171 Nigeria, where only 1 out of 4 patients persisted in treatment for one year [27]. Research evidence

172 from other parts of the globe including North America, Europe and Asia have also demonstrated low

173 rates of persistence in treatment among patients with schizophrenia [4, 5, 34-38].

174 The current study found no significant difference in treatment persistence between patients receiving 175 depot and oral antipsychotics. Previous research on this subject demonstrated divergent findings. 176 While some authors reported that patients with schizophrenia or first episode psychosis treated with 177 depot antipsychotics had significantly longer time to discontinuation of treatment compared to patients 178 on oral antipsychotics [15, 17, 39-43] others found no association between treatment persistence and route of administration of antipsychotics [15,17-22]. The largest meta-analysis of randomised 179 180 controlled trial on this subject comparing depot versus oral medication among patients with 181 schizophrenia found no significant difference [16, 22]. It was envisaged that long acting injections 182 would facilitate monitoring of treatment compliance, thereby guaranteeing administration of 183 medications and transparency of adherence [16]. Consequently, it was anticipated that this would 184 allow the clinicians to be promptly alerted and intervention instituted if patients fail to receive their 185 depot medications.

186 In the current study, patients who received depot medication prescriptions had shorter persistence in 187 treatment compared with patients receiving oral antipsychotics alone. Studies have shown that 188 patients may perceive long acting anti-psychotic injections as coercive and stigmatizing, and such attitudes could consequently lead to non-adherence [44]. Furthermore, the injections are associated 189 190 with tissue irritation and pain which may discourage persistent compliance. However, it is very 191 pertinent to note that evidence have shown that clinicians are more likely to prescribe depot form of 192 medications to patients with past history of poor adherence with oral medications and those with a 193 past history of relapse [16, 45]. On the other hand, patients with high level of insight and good therapeutic alliance are more likely to receive prescriptions of oral medications than long acting 194 injections [16, 45]. Consequently, the low rate of treatment persistence among patients receiving 195 depot antipsychotics could be attributed to the fact that patients selected by clinicians to receive depot 196 197 medication prescription were possibly those to at high risk of drop-out from treatment. In this context,

198	it could be argued that lack of	significant difference in treatment i	persistence between this presumably

- 199 'high-risk' cohort of patients (on depot prescription) versus 'low-risk' patients on (oral medications) is
- 200 consistent with the superiority of depot medication reported in literature [15, 17, 39-43].

201	The high rate of drop-out from treatment, even among patients who received long acting anti-
202	psychotic injection prescription is a worrisome finding because of the associated increased risk of
203	relapse, re-hospitalisation and burden of treatment [6-10]. This is particularly important in a low-
204	resourced country where community based mental health resources are scarce, and prescription of
205	long-acting injections to patients perceived to have a high risk of default may be one of the few or
206	perhaps the only feasible 'intervention' relied on to facilitate persistence in treatment. This finding
207	highlights the need for other interventions to facilitate persistence in treatment among patients with
208	schizophrenia.

209	Patients with schizophrenia and their informal caregivers must be educated on the chronic nature of
210	the disease and the consequences of discontinuation of treatment. Specifically, their understanding of
211	the relapsing nature of the disorder, need for treatment adherence and role of depot and oral
212	medications must be addressed before discharge. This is particularly important considering the
213	widespread belief in traditional and spiritual healers in Nigeria. Furthermore, advocacy efforts must
214	be stepped up in order to ensure that barriers to treatment persistence such as poor access to mental
215	health services, poor mental health care financing, non-integration of mental health into primary care
216	and stigma are addressed by policy makers [23, 46, 47]. Other possible interventions include
217	telephone or online reminders to patients, home visiting teams that can administer injections and
218	dispense drugs, teaching of family members or informal caregivers the technique of administering
219	depot medications, use of longer lasting depot medications, and mobile hospital units especially for
220	patients in rural areas.
221	In comparing this study with previous research on this subject, it is important to note that the patients
222	receiving depot medications were also using oral anti-psychotics concomitantly. The current study is
223	limited by its retrospective design which precludes face to face interview with service users and

- 224 consequently information on the specific barriers to persistence in treatment. For instance, distance
- 225 and other difficulties with accessing services may affect drop-out rate. The support available to

226 facilitate clinic attendance, especially for women traditionally fostered with the care of children and

other culturally designated domestic roles, is also not clear. Furthermore, since most mental health facilities in Nigeria accept patients without formal referrals, patients who appear to have dropped out of treatment may have opted to continue treatment in another facility without documentation. In addition, Finally data retrieved from health records may be limited by missing data and errors of documentation. The major strength of the current study lies in the standardised approach used to estimate treatment persistence, in consistence with previous research. Furthermore, the naturalistic design of the study which bars the influence of the researcher, or any other form of inducement that could preferentially facilitate treatment persistence in any of the study groups also adds to the strength of the study.

236 CONCLUSION

The current study found a high rate of drop-out from out-patient treatment among patients with schizophrenia post-hospitalisation. There was no significant difference in persistence in treatment between patients receiving long acting anti-psychotics injections and those receiving only oral antipsychotics. These findings highlight the need for interventions to minimise drop-out from treatment among patients with schizophrenia.

244 REFERENCES

246	1.	Wyat RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 1991;
247		17 (2):325–351.
248	2.	Harrow M, Jobe TH, Grossman LS, Ghogari V, Faull RN. Lifetime antipsychotic treatment for
249		all schizophrenia patients? A 26-year evidence-based approach. Schizophrenia Bulletin,
250		2011; 37(1):1–342.
251	3.	Malan RD, Luchins DJ, Fichtner CG et al. Discontinuity of outpatient antipsychotic
252		pharmacotherapy: risperidone maintenance after hospitalization. J Pharm Technol. 2001; 17:
253		90-94.
254	4.	Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and
255		persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with
256		schizophrenia. Patient Prefer Adherence. 2008;2:67–7
257	5.	Alene M, Wiese MD, Angamo MT et al. Adherence to medications for the treatment of
258		psychosis: rates and risk factors in an ethopian population. BMC Pharmacology and
259		toxicology. 2012; 12 (10):1-9.

260	6.	Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication
261		therapy in the treatment of schizophrenia. Psychiatric Services. 2003; 54:508–16.
262	7.	Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients
263		with schizophrenia at increased risk for admission. Med Care. 2002; 40:630-9.
264	8.	Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication
265		and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry.
266		2004; 161:692–9.
267	9.	Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among
268		California Medicaid patients with schizophrenia. Psychiatric Services. 2004; 55:886–91.
269	10.	Cullen BA, Mc Ginty EE, Zhang Y et al. Guideline-concordant antipsychotic use and mortality
270		in schizophrenia. Schizophr Bull. 2013; 39 (5): 1159-68.
271	11.	Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in
272		unstable schizophrenia. New England Journal of Medicine. 2011; 364 (9):842–851.
273	12.	Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot
274		antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry. 2011; 179:
275		290–299.
276	13.	Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot
277		antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of
278		randomised long-term trials. Schizophrenia Research. 2011; 127 (1–3):83–92.
279	14.	Schooler NR, Levine J, Severe JB. Prevention of relapse in schizophrenia. An evaluation of
280		fluphenazine decanoate. Archives of General Psychiatry. 1980; 37(1):16–24.
281	15.	Zhornitsky S and Stip E. Oral versus Long acting injectable antipsychotics in the treatment of
282		schizophrenia and special populations at risk for treatment non-adherence: A systematic
283		Review. Schizophrenia Research and Treatment. 2012; Article ID 407171:1-12.
284	16.	Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable
285		antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in
286		Psychopharmacology.2014; 4(5): 198-219.
287	17.	Kaplan G, Casoy J, Zummo J. Impact of long -acting injectable antipsychotics on medication
288		adherence and clinical, functional and economic outcomes of schizophrenia. Patient
289		Preference and Adherence. 2013; 7: 1171-1180.
290	18.	Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting
291		fluphenazine, haloperidol, or risperidone. Schizophrenia Bulletin. 2007; 33 (6): 1379–1387.
292	19.	Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in
293		unstable schizophrenia. N Engl J Med. 2011;364 (9):842–851.
294	20.	Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v oral
295		antipsychotics in schizophrenia: systematic review of randomised controlled trials and
296		observational studies. Br J Psychiatry Suppl. 2009; 52: S20–S28.
297	21.	Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-
298		acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin
299		Psychopharmacol. 2013; 28(2):57–66.

300	22. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for
301	relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull.
302	2014; 40: 192–213.
303	23. Adelekan MO, Ogunlesi AO. Defaulting at a Nigerian National Neuro-psychiatric Hospital.
304	Psychiatric Bulletin. 1990; 14 (7): 403–405.
305	24. Adeponle AB, Thombs BD, Adelekan ML, Kirmayer, L.J. Family participation in treatment,
306	post-discharge appointment and medication adherence at a Nigerian Psychiatric Hospital.
307	British Journal of Psychiatry. 2009; 194, 86-87.
308	25. Adewuya AO, Owoeye OA, Erinfolami AR, et al. Prevalence and correlates of poor
309	medication adherence amongst psychiatric outpatients in southwestern Nigeria. Gen Hosp
310	Psychiatry. 2009; 31 (2): 167-74.
311	26. Adeosun II, Ogun OC, Ijarogbe TG, et al. Pattern of Defaulting from a Nigerian Child and
312	Adolescent Psychiatric Clinic. Nigerian Journal of Psychiatry. 2012; 10 (3), 13-17.
313	27. Esan O. Persistence in treatment for one year among patients in Nigeria with first episode
314	schizophrenia. Psychiatric Services. 2014; 65 (9), 1174-1176.
315	28. Adeosun II. Treatment persistence associated with typical versus atypical antipsychotics
316	among patients with schizophrenia. British Journal of Pharmaceutical Research. 2016; 10 (4),
317	1-8.
318	29. World Health Organization. International Classification of Diseases (ICD-10). Geneva. 1992.
319	30. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical
320	antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006b; 6:8.
321	31. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a
322	difference between typical and atypical agents? Am J Psychiatry. 2002; 159:103–8.
323	32. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of
324	medication adherence with hospitalization and costs. Psychiatr Services. 2001; 52:805–11.
325	33. Kessler TC, Wai O, Demler, Walters EE. Prevalence, severity, and comorbidity of 12-month
326	DSM-IV disorders in the national comorbidity survey replication. Archives of General
327	Psychiatry. 2005; 62 (6): 617–627.
328	34. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in
329	schizophrenia: empirical and clinical findings. Schizophr Bull. 1997; 23:637–65
330	35. Young JL, Zonana HV, Shepler L: Medication noncompliance in schizophrenia: codification
331	and update. Bull Am Acad Psychiatry Law. 1986; 14:105–122
332	36. Mitchell AJ and Selmes T. Why don't patients attend their appointments? Maintaining
333	engagement with psychiatric services. Advances in Psychiatric treatment. 2007; 13: 423-434.
334	37. Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first and second-
335	generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Res.
336	2011; 131 (1-3): 127-32.
337	38. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among
338	patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;
339	67 (10): 1542-50.

- 340 39. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to
 341 discontinuation of depot and oral first-generation antipsychotics in the usual care of
 342 schizophrenia. Psychiatric Services. 2008; 59 (3): 315–317.
- 40. Kim B, Lee SH, Choi TK et al. Effectiveness of risperidone long-acting injection in firstepisode schizophrenia: in naturalistic setting. Progress in Neuro-Psychopharmacology and
 Biological Psychiatry. 2008; 32(5):1231–1235.
- 41. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z. Long-term outcomes
 in patients with schizophrenia treated with risperidone long-acting injection or oral
 antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence
 Registry (e-STAR). Eur Psychiatry. 2009; 24(5):287–296.
- 42. Brnabic AJ, Kelin K, Ascher-Svanum H, Montgomery W, Kadziola Z, Karagianis J. Medication
 discontinuation with depot and oral antipsychotics in outpatients with schizophrenia:
 comparison of matched cohorts from a 12-month observational study. Int J Clin Pract. 2011;
 65(9):945–953.
- 43. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and
 use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for
 schizophrenia. Psychiatr Services. 2007; 58(4):482–488.
- 44. Jaeger M. and Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of
 patients, relatives and psychiatrists. Psychiatry Research. 2010; 175: 58–62.
 - Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P. Clinicians' attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis. 2013; 201: 553–559
 - Klecha D, Barke A, Gureje O. Mental health care in developing countries: the example of Nigeria. Nervencrzt. 2004; 75 (11): 1118-1122.
 - Adeosun II, Adegbohun A, Jeje O, Adewumi A. Experiences of Discrimination by people with Schizophrenia in Lagos Nigeria. Journal of Public Mental Health. 2014; 13(4):189-196
- 364 365 366

359 360

361 362

363